HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Halozyme Therapeutics (HALO) Tops Q2 EPS by 14c, Offers Guidance
August 8, 2023 4:45 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.74, $0.14 better than the analyst estimate of $0.60. Revenue for the quarter came in at $221 million versus the consensus estimate of $199.95 million.
GUIDANCE:
Halozyme Therapeutics sees FY2023 EPS of $2.65-$2.75, versus the consensus of $2.61.... More
